Our Vision
Advancing bold therapeutic innovation and inspiring transformation in the global retinal community.
Our Mission
Dedicated to improving and protecting vision in people with retinal diseases.
Company Overview
Opthea Limited (NASDAQ: OPT, ASX: OPT) is a global biopharmaceutical company aspiring to become the leader of therapeutic innovation in retinal diseases.
We started with a vision of the future, where the impact of retinal disease is reduced, and patients’ quality-of-life is enhanced. With people as our focus, we assembled a world-class team of ophthalmology experts in pursuit of breakthrough therapies. Together we focused on scientific innovation for those who suffer from retinal disease. Today, we are translating our discoveries into promising new medicines.
Management Team
Our executive leadership team has the experience, determination, and resources to make a positive and significant impact on the retinal community. We are building a culture of success that drives our transformation and leadership role as an important global ally in retinal care. Click the links below to learn more about the people who are leading our patient-focused mission.
Fred Guerard • PharmD, MS
Chief Executive Officer
Peter Lang • MBA
Chief Financial Officer
Megan Baldwin • PhD, MAICD
Founder, Chief Innovation Officer and Executive Director
Judith Robertson • MBA
Chief Commercial Officer
Julie Clark • MD
Senior Vice President of Clinical Development
Fang Li • PhD
Senior Vice President Regulatory Affairs
Bruno Gagnon • BPharm, MSc
Senior Vice President, Global Clinical Operations
Karen Adams • B.BBUS, CPA, GAICD, FCC GFIA
Vice President Finance and Company Secretary
Mark O’Neill
Vice President CMC
John Han • PharmD
Vice President, Medical Affairs
Mike Gerometta • PhD
Head of CMC Development
Sarika Gulhar • PhD
Executive Director of Human Resources
Ian Leitch • PhD
Director of Clinical Research
Board of Directors
Our board believes in the promising future of our company and in the power of our transformational science and technology to establish a new standard-of-care for retinal diseases. Our board members bring the strategic expertise and necessary skills needed to help the company succeed, and collectively they provide important oversight and governance of the business.
Jeremy Levin
Chairman of the Board
Megan Baldwin
Founder, Chief Innovation Officer and Executive Director
Lawrence Gozlan
Non-Executive Director
Julia Haller
Non-Executive Director
Susan Orr
Non-Executive Director
Quinton Oswald
Non-Executive Director
Anshul Thakral
Non-Executive Director
Sujal Shah
Non-Executive Director
Board of Directors Committee Composition
Board of Directors Committee Composition
Jeremy Levin
- Nominations & Governance Committee Member
Sujal Shah
- Audit & Risk Committee Chair
Julia Haller
- Research & Development Committee Member
Lawrence Gozlan
- Remuneration Committee Chair
- Nominations & Governance Committee Member
Susan Orr
- Research & Development Committee Chair
- Audit & Risk Committee Member
Quinton Oswald
- Remuneration Committee Member
- Research & Development Committee Member
- Audit & Risk Committee Member
Anshul Thakral
- Nominations & Governance Committee Chair
- Remuneration Committee Member
- Research & Development Committee Member
Fred Guerard, CEO
- Research & Development Committee – Ex Officio
Clinical Advisory Board
Opthea engages with Clinical Advisors who are aligned with our patient-centric mission to obtain independent expert advice.
Tim Jackson
PhD, MB, ChB, FRCOphth • National Health Service Consultant Ophthalmic Surgeon at King’s College Hospital, London
Jason Slakter
MD • Clinical Professor of Ophthalmology at New York University School of Medicine, and partner at Vitreous Retina Macula Consultants Of New York
Charles C. Wykoff
MD, PhD • Director of Research, Retina Consultants of Texas; Chairman of Research and Clinical Trials Committee, Retina Consultants of America; Deputy Chair for Opthalmology, Blanton Eye Institute, Houston Methodist Hospital
Medical Advisors
Opthea engages with Medical Advisors who are aligned with our patient-centric mission to obtain independent expert advice to support sozinibercept development and launch preparation.
Arshad M. Khanani • MD, MA, FASRS
Chief Medical Advisor
Managing Partner, Director of Clinical Research and Director of Fellowship at Sierra Eye Associates, and Clinical Associate Professor at the University of Nevada, Reno School of Medicine.
